ZyVersa Therapeutics, Inc. Warrants
ZVSAW
ZVSAW was delisted on the 20th of December, 2022.
14 hedge funds and large institutions have $2.07M invested in ZyVersa Therapeutics, Inc. Warrants in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Cohanzick Management
Pleasantville,
New York
|
+$106K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$106K |
| 3 |
RA
RiverPark Advisors
New York
|
+$106K |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
+$75.9K |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$56.2K |
Top Sellers
ZVSAW Hedge Fund Activity: Q1 2022 in Review
14 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q1 2022, worth a combined $2.07M.
Buyers outnumbered sellers: 14 funds opened new ZVSAW positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cohanzick Management, opening a new position worth an estimated $106K.
- 14 institutional investors held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $2.07M of ZyVersa Therapeutics, Inc. Warrants stock for Q1 2022.
- 14 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q1 2022 and 0 closed out, a net change of +14 holders.
- The largest ZyVersa Therapeutics, Inc. Warrants buyer in Q1 2022 was Cohanzick Management, an estimated $106K added.
Based on aggregated 13F filings for Q1 2022.